Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gordon James Freeman, Ph.D.

Co-Author

This page shows the publications co-authored by Gordon Freeman and Eliezer Van Allen.
Connection Strength

0.483
  1. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204.
    View in: PubMed
    Score: 0.175
  2. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.055
  3. Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
    View in: PubMed
    Score: 0.055
  4. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.053
  5. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 09 25; 10(1):4346.
    View in: PubMed
    Score: 0.052
  6. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018 07 26; 174(3):549-563.e19.
    View in: PubMed
    Score: 0.048
  7. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.